Who Can Take Mounjaro: Eligibility, Criteria and What to Expect

Step 1: Does your BMI put you in scope?

The starting point for anyone asking who can take Mounjaro in the UK is the BMI threshold written into the medicine's licence. A BMI of 30 or above qualifies on its own. If your BMI sits between 27 and 29.9, at least one weight-related comorbidity needs to be present — conditions that count include type 2 diabetes, prediabetes, high blood pressure, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea and osteoarthritis. The BMI required for Mounjaro is worth checking precisely, because thresholds matter in practice. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, UK guidance typically applies a 2.5 kg/m² reduction to both thresholds, so 27.5 can qualify where 30 would otherwise be required.

BMI is a useful starting signal, but a number alone never decides suitability. A prescriber weighs your current health status, medical history and any medicines you already take. The NHS BMI calculator is a practical first check if you want a quick sense of where you stand before a consultation.

NICE's appraisal of tirzepatide (TA1026) sets slightly stricter criteria for NHS access, but private prescribing follows the licensed indications from the medicine's SmPC. The two are related but not identical, a detail worth understanding if you are comparing NHS and private routes.

Step 2: Medical history the prescriber will review

Once the BMI threshold is confirmed, the prescriber moves to a broader clinical review. Some conditions require particular care. A personal or family history of medullary thyroid carcinoma, or a diagnosis of multiple endocrine neoplasia type 2 (MEN2), are listed in the SmPC as reasons Mounjaro should not be used. Pancreatitis (both a current episode and a documented history) requires careful discussion, since tirzepatide carries a known association with acute pancreatitis. In January 2026, the MHRA issued a Drug Safety Update reinforcing that GLP-1 medicines including tirzepatide can cause acute pancreatitis in rare cases; prescribers factor this into their assessment of suitability.

Severe gastrointestinal conditions, kidney impairment at certain stages, and some other chronic diagnoses may also influence the decision. This is exactly the kind of nuance that a list of who cannot take Mounjaro can help clarify, though the final call always belongs to the prescriber reviewing your full medical record. Our clinical team is available to answer questions before you formally begin a consultation.

Interactions with other medicines are another consideration. The gastric-emptying effect of tirzepatide can influence how quickly other oral medicines are absorbed, which matters for some treatments. If you take naproxen regularly, for instance, it is worth reading about taking naproxen alongside Mounjaro before you start.

Step 3: Groups for whom Mounjaro is not recommended

Certain groups sit outside the licensed indications regardless of BMI. Mounjaro is not licensed for anyone under 18. It is not recommended during pregnancy, whilst breastfeeding, or for people who are actively trying to conceive. The MHRA advises using effective contraception during treatment; women taking oral contraceptives should add a barrier method for the first four weeks of Mounjaro and for four weeks after any dose increase, since the medicine's effect on gastric emptying can reduce how reliably the pill is absorbed.

These exclusions are not arbitrary caution. The evidence base for tirzepatide in pregnancy simply does not exist, and the conservative approach reflects that gap. If your circumstances change during treatment (a surprise pregnancy, for instance) the right step is to contact your prescriber the same day. Our prescribers are available seven days a week for exactly this kind of aftercare question. You can find fuller background on eligibility, including the overlap with NHS criteria, on our guide to getting Mounjaro in the UK.

It is also worth noting what Mounjaro is not: it is licensed for weight management alongside a reduced-calorie diet and increased physical activity, not as a standalone fix. Prescribers look for a realistic picture of lifestyle intent as part of the assessment.

Step 4: What the consultation itself involves

If the criteria above suggest you are likely eligible, the next step is a structured clinical consultation. At nume, this means filling in a detailed medical questionnaire; your answers are read the same day by a GPhC-registered Independent Prescriber, a real clinician, not automated decision software. Identity is verified with photo ID, and weight is confirmed on a live video call, so the BMI figure on your form is the same one the prescriber uses to make their decision.

If approved as clinically suitable, and your order is placed before noon, your treatment is dispatched that afternoon and arrives the next working day via tracked DPD in plain, unbranded packaging. There is no subscription and no auto-renewal; every repeat order goes through a fresh clinical review. Our Mounjaro overview page covers how the medicine works, what the treatment schedule looks like, and what to expect in the first few weeks. For a broader look at all licensed weight-loss options, the treatment options page is a useful place to compare. You can also read about whether Mounjaro is right for you before committing to a consultation.

One thing our prescribers are asked regularly: does having a weight-related condition automatically mean approval? It does not. Eligibility opens the door; clinical suitability decides whether you walk through it. If you have questions before starting, the FAQs page covers the most common ones. When you are ready, speaking to our prescribers is the most direct route to a clear answer for your specific situation.